Biomea Fusion, Inc. (BMEA)
After hours:
| Previous Close | 4.63 |
| Open | 4.95 |
| Bid | 5.80 x 400 |
| Ask | 5.83 x 100 |
| Day's Range | 4.89 - 6.09 |
| 52 Week Range | 3.61 - 38.84 |
| Volume | |
| Avg. Volume | 1,238,463 |
| Market Cap | 208.838M |
| Beta (5Y Monthly) | -0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.55 |
| Earnings Date | Apr 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.83 |
Insider MonkeyBiomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays
We recently compiled the list of the Analysts on Wall Street Lower Ratings for These 10 Stocks. In this article, we are going to take a look at where Biomea Fusion, Inc. (NASDAQ:BMEA) stands against the other stocks that received a downgrade from Wall Street analysts. But first, we are going to take a look at […]
Investor's Business DailyBiomea Fusion Crashes 63% After FDA Puts Diabetes Treatment Studies On Hold
Biomea stock crashed Friday after the FDA placed two of the company's diabetes treatment studies on hold, citing concerns of liver toxicity.
GlobeNewswireBiomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. The Company will continue ongoing safety and efficac
